LY 3872386
Alternative Names: LY-3872386Latest Information Update: 05 Aug 2024
At a glance
- Originator Eli Lilly and Company
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis
Most Recent Events
- 25 Jul 2024 Eli Lilly and Company terminates a phase I trial in Atopic dermatitis (In volunteers) in USA (IV), based on emerging nonclinical data (NCT06119529)
- 25 Jul 2024 Eli Lilly and Company terminates a phase I trial in Atopic dermatitis (In volunteers) in USA (SC), based on emerging nonclinical data (NCT06119529)
- 07 Nov 2023 Preclinical trials in Atopic dermatitis in USA (SC) prior to November 2023 (NCT06119529)